QT VASCULAR LTD.
(Company Registration No. 201305911K)
(Incorporated in Singapore)
("**Company**")

US$1.86 MILLION EXCHANGEABLE BONDS AND US$4.20 MILLION CONVERTIBLE BONDS - RECEIPT OF LISTING AND QUOTATION NOTICE

Reference is made to the Company's announcement of 27 January 2016 in relation to its proposed issue of 8% exchangeable bonds due in 2017/2018 ("Exchangeable Bonds") of US$1.86 million and 8% convertible bonds due in 2017/2018 ("Convertible Bonds") of US$4.20 million (collectively the "**Bonds**"). All capitalised terms used herein shall have the meanings ascribed in the aforesaid announcement.

The Board of Directors of the Company is pleased to announce that the Company has on 24 February 2016 received a listing and quotation notice from the SGX-ST ("**L&Q Notice**") for the listing and quotation of up to 65,334,375 Conversion Shares comprising 20,053,125 Exchange Shares and 45,281,250 Conversion Shares to be issued and allotted upon conversion of the Exchangeable Bonds and Convertible Bonds respectively, at a fixed conversion price of S$0.128, based on the currency exchange rate of S$1.38 to US$1.00.

The listing and quotation of the Exchange Shares and the Conversion Shares is subject to the following conditions:

1. Compliance with the SGX-ST's listing requirements;

2. Disclosures in the shareholders' circular and in an announcement, the rationale for terms to require the Company and Quattro Vascular Pte. Ltd. ("**Quattro Vascular**"), as the case may be, to pay in full, the principal amount of Bonds subscribed by each Subscriber on maturity, irrespective of whether the Subscribers have converted or exchanged their Bonds into New Shares (the "**Payment on Maturity Terms**");

3. Disclosures in the shareholders' circular and in an announcement that the terms of issuance of the Bonds are similar to the terms of issuance of convertible bonds that were announced on 24 July 2015. The Board should provide its opinion (including relevant basis) on why such terms are in the best interests of the Company; and

4. Shareholders' approval obtained for the issuance of the Exchangeable Bonds and/or the Exchange Shares to Luminor Pacific Fund 2 Ltd at an EGM to be convened.

In relation to the aforementioned conditions 2 and 3, the terms of the Bonds announced on 27 January 2016 is similar to the terms (including the Payment on Maturity Terms) of the convertible bonds announced on 24 July 2015, both of which were commercially agreed between the Company and/or Quattro Vascular, a wholly owned subsidiary of the Company, and the investors. Such terms of the Bonds are necessary to attract investors to invest in the Company's Bonds in light of (i) the current market conditions; (ii) the timing required to ensure that the Group's working capital financing needs are met; and (iii) the ongoing litigation with AngioScore, Inc..

The Board is of the opinion that the terms of the Bonds are commercially reasonable in terms of fund raising costs and potential short-term dilution to existing shareholders when compared to various other fund raising options that are available to the Company.

The L&Q Notice is not an indication of the merits of the New Shares, Subscribers, the Bonds, the Company, its subsidiaries and their securities.

The Company will further update shareholders on completion of the subscription and issue of the US$1.86 million Exchangeable Bonds and US$4.20 million Convertible Bonds and if there are any other material developments in relation to the Bonds.

By Order of the Board
QT VASCULAR LTD.

Eitan Konstantino
Chief Executive Officer
25 February 2016

---

*The Company was listed on Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**").*

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.